Non-alcoholic Fatty Liver Disease
"Non-alcoholic Fatty Liver Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Fatty liver finding without excessive ALCOHOL CONSUMPTION.
| Descriptor ID |
D065626
|
| MeSH Number(s) |
C06.552.241.519
|
| Concept/Terms |
Non-alcoholic Fatty Liver Disease- Non-alcoholic Fatty Liver Disease
- Non alcoholic Fatty Liver Disease
- NAFLD
- Nonalcoholic Fatty Liver Disease
- Fatty Liver, Nonalcoholic
- Fatty Livers, Nonalcoholic
- Liver, Nonalcoholic Fatty
- Livers, Nonalcoholic Fatty
- Nonalcoholic Fatty Liver
- Nonalcoholic Fatty Livers
Nonalcoholic Steatohepatitis- Nonalcoholic Steatohepatitis
- Nonalcoholic Steatohepatitides
- Steatohepatitides, Nonalcoholic
- Steatohepatitis, Nonalcoholic
|
Below are MeSH descriptors whose meaning is more general than "Non-alcoholic Fatty Liver Disease".
Below are MeSH descriptors whose meaning is more specific than "Non-alcoholic Fatty Liver Disease".
This graph shows the total number of publications written about "Non-alcoholic Fatty Liver Disease" by people in this website by year, and whether "Non-alcoholic Fatty Liver Disease" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 6 | 6 |
| 2012 | 0 | 4 | 4 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 7 | 0 | 7 |
| 2016 | 10 | 2 | 12 |
| 2017 | 12 | 1 | 13 |
| 2018 | 16 | 0 | 16 |
| 2019 | 18 | 2 | 20 |
| 2020 | 12 | 0 | 12 |
| 2021 | 18 | 1 | 19 |
| 2022 | 15 | 0 | 15 |
| 2023 | 30 | 0 | 30 |
| 2024 | 8 | 1 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Non-alcoholic Fatty Liver Disease" by people in Profiles.
-
NAFLD No More: A Review of Current Guidelines in the Diagnosis and Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Curr Diab Rep. 2024 Nov 13; 25(1):5.
-
Semaglutide 2.4?mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 2024 Dec; 60(11-12):1525-1533.
-
Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis. Clin Gastroenterol Hepatol. 2024 Dec; 22(12):2367-2377.
-
Cost burden of cirrhosis and liver disease progression in metabolic dysfunction-associated steatohepatitis: A US cohort study. J Manag Care Spec Pharm. 2024 Sep; 30(9):929-941.
-
Envisioning how to advance the MASH field. Nat Rev Gastroenterol Hepatol. 2024 Oct; 21(10):726-738.
-
Use of non-invasive diagnostic tools for metabolic dysfunction-associated steatohepatitis: A qualitative exploration of challenges and barriers. Liver Int. 2024 Aug; 44(8):1990-2001.
-
Steatotic liver disease: a new name to reflect the combined role of alcohol and metabolic dysfunction. Nat Med. 2024 Apr; 30(4):933-936.
-
Clinical Guidelines on Nonalcoholic Fatty Liver Disease-Reply. JAMA. 2024 03 26; 331(12):1063-1064.
-
Reply: NAFLD vs. MASLD-There ain't no such thing as a free lunch. Hepatology. 2024 Jul 01; 80(1):E13-E14.
-
Macrophage RAGE activation is proinflammatory in NASH. JCI Insight. 2024 Feb 08; 9(3).